Document is current
Any future updates will be listed below
-
Authors
Weber-Stiehl, Saskia
Taubenheim, Jan https://orcid.org/0000-0001-7283-1768
Järke, Lea
Röcken, Christoph
Schreiber, Stefan
Aden, Konrad
Kaleta, Christoph
Rosenstiel, Philip
Sommer, Felix
-
Funding
Funding for this research was provided by:
Universitätsklinikum Schleswig-Holstein - Campus Kiel
- License Information
-
More Information
Article History
Received: 7 June 2024
Accepted: 16 October 2024
First Online: 23 October 2024
Declarations
:
: All research complied with relevant ethical regulations, and usage of human tissue material and transcriptome data was approved by the ethics committee of the Medical Faculty at Kiel University (A156/03, A124/14, A102/16).
: Not applicable.
: SS reports indirect stock ownership in Gerion Biotech GmbH as well as consulting and personal fees from AbbVie, Allergosan, Amgen, Arena, BMS, Biogen, Celltrion, Celgene, Falk, Ferring, Fresenius, Galapagos/Gilead, HIKMA, I-Mab, Janssen, Lilly, Morphic, MSD, Mylan, Pfizer, Prometheus, Protagonist, Provention Bio, Sandoz/Hexal, Takeda, and Theravance. PR reports stock ownership in Gerion Biotech GmbH and consulting fees from Takeda. All other authors declare no competing interests.
